CAN.AU Cann Group Ltd

Healthcare Pharmaceuticals Australian Securities Exchange
0.0050 AUD
Close of Oct 29, 2026
0.0020 0.0130
Market cap
AUD 8.30M
P/E
0.3x
P/B
0.29x
ROE
71.0%
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CAN.AU undervalued?

Graham number

The Graham number of Cann Group Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cann Group Ltd fundamental analysis

9 of 22 checks passed

ROE 2/2

High return on equity (71.0%), above 20%.

ROA 1/1

Return on assets (39.0%) is above the industry median (-8.9%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (139.4%) is above the industry median (42.8%).

Revenue Growth 0/2

Revenue shrank 14.7% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (58.9%), up to 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is negative, against interest expense, below 5x.

PE vs Market 1/1

PE (0.3x) is below the market median (15.0x).

PE vs Industry 1/1

PE (0.3x) is below the industry median (21.9x).

PBV 1/1

Price to book (0.3x) is below the industry median (2.0x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 0.1, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Cann Group Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cann Group Ltd

Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.

Full company profile